nach oben

Current Bladder Dysfunction Reports

Erschienen in:

01.03.2016 | Stress Incontinence and Prolapse (R Dmochowski, Section Editor)

Lessons Learned from Mesh Litigation for Prolapse and Incontinence

verfasst von: Elizabeth Timbrook Brown, Joshua A. Cohn, Melissa R. Kaufman, W. Stuart Reynolds, Roger R. Dmochowski

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) can cause significant impairment in quality of life and lead many women to seek surgical correction. These procedures are often performed using polypropylene mesh. The Food and Drug Administration (FDA) issued a Public Health Notification to inform patients of adverse events related to the use of mesh placed in these repairs. Since this time, there have been almost 50,000 legal proceedings related to complications of polypropylene mesh in the urogynecology setting. Currently, the FDA is conducting further studies to evaluate the safety and efficacy of polypropylene mesh, but it is still available for use in the repair of SUI and POP. Thus, patients should be carefully selected and counseled appropriately regarding conservative management options and alternative surgical therapies prior to mesh placement. As a result of the FDA recommendations, researchers are currently trying to develop a treatment alternative to mesh.

Togami J, Brown E, Winters JC. Vaginal mesh-the controversy. F1000 Med Rep. 2012;2:21.

Mock S, Angelle J, Reynolds WS, et al. Contemporary comparison between retropubic midurethral sling and autologous pubovaginal sling for stress urinary incontinence after the FDA advisory notification. Urology. 2015;85:321–25.CrossRefPubMed

Sivaslioglu A, Unlubilgin E, Dolen I. A randomized comparison of polypropylene mesh surgery with site specific surgery in the treatment of cystocele. Int Urogynecol J. 2008;19:467–71.CrossRef

4.••

FDA public health notification: serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse and stress urinary incontinence. [http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm]. This website delineates the 2011 FDA Safety Communication and a summary of the MAUDE database reports.

Kuhlmann-Capek M, Kilic G, Shah A, et al. Enmeshed in controversy: use of vaginal mesh in the current medicolegal environment. Female Pelv Med Reconstr Surg. 2015;21(5):241–3.CrossRef

Drutz HP, Alarab M. Pelvic organ prolapse: demographics and future growth prospects. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17 Suppl 1:S6.CrossRefPubMed

Koski M, Rovner E. Implications of the FDA statement on transvaginal placement of mesh: the aftermath. Curr Urol Rep. 2014;15:380.CrossRefPubMed

Urogynecologic surgical mesh implants. The US Food and Drug Administration (FDA) [http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm262301.htm].

Premarket notification (510k): the US Food and Drug Administration [www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/510kclearances/default.htm.

10.

Chapple C, Raz S, Brubaker L, et al. Mesh sling in an era of uncertainty: lessons learned and the way forward. Eur Urol. 2013;64:525–29.CrossRefPubMed

11.

MAUDE-Manufacturer and User Facility Device Experience: The US Food and Drug Administration. [www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm].

12.

Considerations for surgical mesh for SUI: the US Food and Drug Administration [http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm345219.htm].

13.

“FDA’s Roles and Activities” The US Food and Drug Administration [http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm262301.htm].

14.••

Federal Register: reclassification of surgical mesh for transvaginal pelvic organ prolapse [www.federalregister.gov/articles/2014/05/01/2014-09907/reclassification-of-surgical-mesh-for-transvaginal-pelvic-organ-prolapse-repair-and-surgical]. This website delineates the reclassification of mesh that was ordered after the results of the MAUDE database were evaluated.

15.

Wood L, Anger J. Urinary incontinence in women. BMJ. 2014;349:g4531.CrossRefPubMed

16.

Pelvic Floor Disorders Registry: [www.pfdr.org].

17.

Koski M, Chamberlain J, Rossof J, et al. Patient perception of transvaginal mesh and the media. Urology. 2014;84:575–82.CrossRefPubMed

18.

Brown LK, Fenner DE, Berger MB, et al. Defining patients’ knowledge and perceptions of vaginal mesh surgery. Female Pelvic Med Reconstr Surg. 2013;19(5):282–7.CrossRefPubMedPubMedCentral

19.

GoogleTM search term “transvaginal mesh” performed September 26, 2015.

20.

Sadiq A, Mitchell S, Rosenblum N, et al. YouTube as a source for vaginal mesh information. J Urol. 2014;191(4S):e783.CrossRef

21.

Tenggardjaja C, Moore C, Vasavada S, et al. Evaluation of patients’ perceptions of mesh usage in female pelvic medicine and reconstructive surgery. Urology. 2015;85:326–32.CrossRefPubMed

22.

Yanagisawa M, Rhodes M, Zimmern P. Mesh social networking: a patient-driven process. BJUI. 2011;108:1539–43.CrossRef

23.

Lawsuit filed Gynecare TVT bladder suspension tape (prolene mesh) [www.topix.com/forum/com/jnj/TTE0RAIRMP5EFC052/p228].

24.

Scott v. Kannappan, S-1500-CV-266034-WDE, Superior Court for Kern County, California.

25.

Nosti P, Iglesia C. Medicolegal issues surrounding devices and mesh for surgical treatment of prolapse and incontinence. Clin Obset Gyn. 2013;56(20):221–28.CrossRef

26.

Transvaginal mesh lawsuit: erosion, surgical, POP & SUI lawyer [www.drugwatch.com/transvaginal-mesh/lawsuit.php].

27.•

American Urologic Association (AUA) position statement on the use of vaginal mesh for repair of pelvic organ prolapse. 2012. [www.auanet.org/education/vaginal-mesh-for-pelvic-organ-prolapse.cfm]. This is the AUA position statement continuing to support the use of TVM for prolapse in certain instances and provides the necessary stipulations for use of TVM.

28.•

American Urologic Association (AUA) position statement on the use of vaginal mesh for the surgical treatment of stress urinary incontinence. 2012[www.auanet.org/education/vaginal-mesh-for-sui.cfm]. This is the AUA position statement continuing to support the use of multi-incision mesh slings stating that there is good evidence for their use.

29.•

Miller D, Milani AL, Sutherland SE. Informed surgical consent for a mesh/graft-augmented vaginal repair of pelvic organ prolapse. Consensus of the 2nd IUGA grafts roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J. 2012;23(supp 1):33. This outlines the IUGA consensus regarding informed consent and implantation practices.CrossRef

30.

Clemons JL, Weinstein M, Guess MK, et al. Impact of the 2011 FDA transvaginal mesh safety update on AUGS members’ use of synthetic mesh and biologic grafts in pelvic reconstructive surgery. Female Pelvic Med Reconstr Surg. 2013;19(4):191–8.CrossRefPubMed

31.

American College of Obstetricians and Gynecologists. Committee opinion no. 513: vaginal placement of synthetic mesh for pelvic organ prolapse,”. Obstet Gynecol. 2011;118(6):1459–64.CrossRef

32.

Menefee SA, Dyer KY, Lukacz ES. Colporrhaphy compared with mesh or graft-reinforced vaginal paravaginal repair for anterior vaginal wall prolapsed: a randomized controlled trial. Obstet Gynecol. 2011;118:1337–44.CrossRefPubMed

33.

Maher C, Feiner B, Bassler K, et al. Surgical management of pelvic organ prolapse in women: the updated Cochrane summary review. Int Urogynecol J. 2011;22:1455–57.

34.

Murphy M, Hozberg A, van Raalte H, et al. Time to rethink: an evidence-based response from pelvic surgeons to the FDA Safety Communication: “UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse”. Int Urogynecol J. 2012;23:5–9.CrossRefPubMed

Titel: Lessons Learned from Mesh Litigation for Prolapse and Incontinence
verfasst von: Elizabeth Timbrook Brown
Joshua A. Cohn
Melissa R. Kaufman
W. Stuart Reynolds
Roger R. Dmochowski
Publikationsdatum: 01.03.2016
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 1/2016
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-016-0353-8

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Lessons Learned from Mesh Litigation for Prolapse and Incontinence

Abstract

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Impact of Caffeine on Overactive Bladder Symptoms

Are Bladder Diaries Helpful in Management of Overactive Bladder?

The Bladder Is Not Sterile: History and Current Discoveries on the Urinary Microbiome

The Role of Mindfulness in Urinary Urgency Symptoms

Urinary Tract Infections in Women: Pathogenesis, Diagnosis, and Management

Bladder Outlet Obstruction After Incontinence Surgery

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie